These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3898130)

  • 1. Criteria for response to treatment of metastatic prostatic cancer.
    Newling DW
    Prog Clin Biol Res; 1985; 185A():205-20. PubMed ID: 3898130
    [No Abstract]   [Full Text] [Related]  

  • 2. Criteria for evaluating patient responses to treatment modalities for prostatic cancer.
    Slack NH; Murphy GP
    Urol Clin North Am; 1984 May; 11(2):337-42. PubMed ID: 6375069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
    Kvols LK; Eagan RT; Myers RP
    Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial.
    Moore MR; Graham SD; Birch R; Irwin L
    Cancer Treat Rep; 1987 Jan; 71(1):89-90. PubMed ID: 3791273
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of trials of the USA National Prostatic Cancer Project.
    Elder JS; Gibbons RP
    Prog Clin Biol Res; 1985; 185A():221-42. PubMed ID: 3898131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective response criteria in prostate cancer.
    Akaza H; Jones WG; Javadpour N; van Oosterom AT; Isaka S; Shimazaki J
    Prog Clin Biol Res; 1990; 357():193-7. PubMed ID: 2217463
    [No Abstract]   [Full Text] [Related]  

  • 7. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
    Halabi S; Small EJ; Vogelzang NJ
    J Clin Oncol; 2005 Apr; 23(10):2434-5; author reply 2435. PubMed ID: 15800342
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of spirogermanium in metastatic prostate cancer.
    Dexeus FH; Logothetis C; Samuels ML; Hossan B
    Cancer Treat Rep; 1986 Sep; 70(9):1129-30. PubMed ID: 3742495
    [No Abstract]   [Full Text] [Related]  

  • 9. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 10. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EORTC Phase III trials in prostatic cancer.
    Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract]   [Full Text] [Related]  

  • 12. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
    Ward JF
    Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
    [No Abstract]   [Full Text] [Related]  

  • 13. Endocrine treatment of cancer of the prostate.
    Madsen PO; Pedersen JF; Knuth OE
    Wis Med J; 1970 Jul; 69(7):177-81. PubMed ID: 4916084
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer chemotherapy: emerging from the shadows.
    Roth BJ
    J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
    Sartor O
    J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
    [No Abstract]   [Full Text] [Related]  

  • 16. Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient.
    Beekman KW; Hussain M
    Urol Oncol; 2008; 26(4):415-9. PubMed ID: 18593620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of palliative treatment of metastasizing prostatic cancer with the prolactin inhibitor parlodel].
    Ausfeld R; Huber P; Del Pozo E
    Helv Chir Acta; 1982 Aug; 49(3-4):459-62. PubMed ID: 6182128
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of prostatic cancer with progestational agents].
    Bouffioux C
    Acta Urol Belg; 1976 Oct; 44(4):336-53. PubMed ID: 1026071
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug development in metastatic prostate cancer.
    Armstrong AJ; George DJ
    Urol Oncol; 2008; 26(4):430-7. PubMed ID: 18593623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.